Recursion Pharmaceuticals (NASDAQ: RXRX) saw its stock drop over 17% week-to-date following a price target cut by Morgan Stanley analyst Sean Laaman, who reduced his fair value estimate by $0.20 to $4.80 while maintaining a hold recommendation. Additionally, regulatory filings indicated that several executives of the clinical-stage biotech company sold significant amounts of stock.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
